Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 13;5(5):CD016070.
doi: 10.1002/14651858.CD016070.

Parallel use of low-complexity automated nucleic acid amplification tests and lateral flow urine lipoarabinomannan assays to detect tuberculosis disease in adults and adolescents living with HIV

Stephanie Bjerrum  1   2 , Bada Yang  3 , Johanna Åhsberg  1   4 , Ruvandhi R Nathavitharana  5 , Laura Olbrich  6 , Devan Jaganath  7 , Alexander W Kay  8 , Andreas Lundh  9   10 , Maunank Shah  11   12
Affiliations

Parallel use of low-complexity automated nucleic acid amplification tests and lateral flow urine lipoarabinomannan assays to detect tuberculosis disease in adults and adolescents living with HIV

Stephanie Bjerrum et al. Cochrane Database Syst Rev. .

Update in

Abstract

This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows: To compare the diagnostic accuracy of parallel use of lateral flow urine lipoarabinomannan on urine and low-complexity automated nucleic acid amplification tests on respiratory samples versus each test alone for detection of tuberculosis disease in adults and adolescents living with HIV who present with presumptive tuberculosis. Secondary objectives To investigate the following sources of heterogeneity: clinical setting; signs and symptoms of tuberculosis; screening positivity for tuberculosis disease by chest x-ray, C-reactive protein elevation, and molecular World Health Organization-recommended rapid diagnostics; seriously ill; advanced HIV; and CD4 cell count.

PubMed Disclaimer

Conflict of interest statement

Development of the systematic review was made possible with a financial support from the World Health Organization (WHO), Switzerland. SB, BY, JÅ, RN, LO, DJ, and MS received funding from the WHO as consultants to the review. AL reported to be a consultant to the WHO, but did not receive funding from the WHO.

SB, JÅ, MS, LO, and DJ were involved in primary studies that may be included in this review. Authors of primary studies will not make study eligibility decisions about, extract data from, carry out the risk of bias assessment for, or perform GRADE assessments of that study.

SB has no additional conflicts of interest to declare.

BY reports employment at Universitair Medisch Centrum Utrecht.

JÅ has no additional conflicts of interest to declare.

RN is the Chair of the TB Proof board and an independent consultant to the WHO.

LO has conducted prior primary research on tuberculosis diagnostics. The Division of Infectious Diseases and Tropical Medicine of the Ludwig‐Maximilians University Munich, where LO is based, received Xpert MTB/RIF Ultra cartridges for free for research use from Cepheid.

DJ has no additional conflicts of interest to declare.

AK has no known conflicts of interest.

AL has no additional conflicts of interest to declare.

MS has no additional conflicts of interest to declare.

Figures

1
1
Clinical pathway for LC‐aNAATs and LF‐LAM in parallel for diagnosis of tuberculosis among adults and adolescents living with HIV Abbreviations: DR‐TB: drug resistant TB; LAM: lipoarabinomannan; LC‐aNAAT: low‐complexity automated nucleic acid amplification test; LF‐LAM: lateral flow lipoarabinomannan assay; mWRD: molecular World Health Organization‐recommended diagnostics; TB: tuberculosis. Footnotes aPeople aged 10 years and above, HIV‐positive, and attending a health facility.
bSystematic screening for TB disease should be conducted if screening positive for TB signs and symptoms including WHO‐recommended symptom screen (i.e. WHO four‐symptom screen) or signs and symptoms of extrapulmonary TB (or both). Other screening tools that may be used include: C‐reactive protein with a cut‐off of greater than 5 mg/L, chest X‐ray, molecular WHO‐recommended rapid tests. The following populations further qualify for TB testing regardless of TB screening result: inpatients in medical wards where the TB prevalence is greater than 10% (molecular WHO‐recommended rapid tests including LC‐aNAAT should be used); inpatients with advanced HIV disease (CD4 less than 200 cells/mm3 or WHO clinical stage 3 or 4 events) or being seriously ill (respiratory rate greater than 30 breaths/minutes or temperature greater than 39 °C or heart rate greater than 120 beats/minute or unable to walk unaided) (LF‐LAM should be used as an add‐on to clinical judgement in combination with other tests); outpatients who are seriously ill or have a CD4 less than 100 cells/mm3 or a WHO clinical stage 3 or 4 event (LF‐LAM should be used as an add‐on to clinical judgement in combination with other tests).
cAmongst inpatients, LF‐LAM may assist in the diagnosis of active TB in HIV‐positive adults and adolescents if: signs and symptoms of TB; or advanced HIV disease; or seriously ill. Amongst outpatients, LF‐LAM may assist in the diagnosis of active TB in HIV‐positive adults and adolescents if: signs and symptoms of TB or seriously ill; or CD4 less than 100 cells/mm3; or a WHO clinical stage 3 or 4 event.
dThe LF‐LAM strip‐test that can detect the LAM antigen in urine at the point‐of‐care. 
eLC‐aNAATs for TB diagnosis and detection of resistance to isoniazid or rifampicin (or both). LC‐aNAATs evaluated in this review include Xpert MTB/RIF and Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, USA); Truenat MTB and MTB Plus (Molbio Diagnostics, Goa, India); STANDARD M10 (SD Biosensor, Republic of Korea); and IRON‐qPCR (BIONEER, Republic of Korea).
fPeople testing positive on either LF‐LAM or LC‐aNAAT are recommended to receive tuberculosis treatment.
See this image and copyright information in PMC

References

    1. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 2015;29(15):1987-2002. [DOI: 10.1097/QAD.0000000000000802] - DOI - PMC - PubMed
    1. World Health Organization. Global tuberculosis report 2023. iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1 (accessed 11 November 2023).
    1. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nature Reviews. Disease Primers 2016;2:16076. [DOI: 10.1038/nrdp.2016.76] - DOI - PubMed
    1. Shivakoti R, Sharma D, Mamoon G, Pham K. Association of HIV infection with extrapulmonary tuberculosis: a systematic review. Infection 2017;45(1):11-21. [DOI: 10.1007/s15010-016-0960-5] - DOI - PMC - PubMed
    1. Kerkhoff AD, Barr DA, Schutz C, Burton R, Nicol MP, Lawn SD, et al. Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays. Scientific Reports 2017;7(1):10931. [DOI: 10.1038/s41598-017-09895-7] - DOI - PMC - PubMed

Publication types